DVONCH JEROME J 4
4 · Sonoma Pharmaceuticals, Inc. · Filed Jul 9, 2026
Research Summary
AI-generated summary of this filing
Sonoma (SNOA) CFO Jerome J. Dvonch Receives 10,000 RSUs
What Happened
Jerome J. Dvonch, Chief Financial Officer of Sonoma Pharmaceuticals (SNOA), was awarded 10,000 restricted stock units (RSUs) on July 9, 2026. The RSUs were granted at $0.00 (no cash purchase); each RSU represents a contingent right to receive one share of common stock upon vesting. This is a compensation grant rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-07-09; Transaction type: Award/Grant (code A).
- Shares/units granted: 10,000 RSUs; grant price reported as $0.00 (derivative award).
- Shares owned after transaction: Not specified in the filing.
- Vesting: RSUs vest on the third anniversary of the grant date or upon a change of control (per footnote).
- Purpose: Award granted for services performed (per footnote).
- Filing timeliness: Reported with period and filing date of 2026-07-09 (timely).
Context
RSUs are a form of equity compensation and do not represent immediate share ownership or a cash investment; they convert into shares only if and when they vest and may be forfeitable until then. Such grants are common executive compensation and do not by themselves indicate an insider buying or selling stock for market speculation.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F3][F2]2026-07-09+10,000→ 44,391 totalExercise: $0.00→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- [F2]The RSUs on the third anniversary of the grant date, or upon change of control.
- [F3]The RSUs were awarded and granted to Mr. Dvonch for services performed.